Skip to content

Drug MonographTirzepatide · GLP-1·GIP

TirzepatideReport
Sections

Tirzepatide monograph · Evidence review

What Dose of Zepbound Is Most Effective?

Zepbound weight loss climbs with dose — 15 mg lost the most in SURMOUNT-1. But the most effective dose isn't always the highest one you can take.

Researched & written by Alan Pierce · last updated

Clinical Pharmacology Writer

If you want the short, evidence-based answer: in the pivotal obesity trials, the highest maintenance dose of tirzepatide (15 mg once weekly) produced the most weight loss on average, with the 10 mg dose close behind and 5 mg clearly lower1. But "most effective" and "best for you" are not the same thing, and treating them as identical is how people end up with worse side effects for little extra benefit. This page lays out what the dose-response data actually shows, where the curve flattens, and why the most effective dose in a trial average may not be the one your body tolerates.

A reminder before the numbers: Zepbound is the FDA-approved brand of tirzepatide for chronic weight management (Mounjaro is the same molecule approved for type 2 diabetes), it is prescription-only, and every dose figure below comes from controlled trials of the brand product — not compounded vials, which are not held to the same standards2.

The approved maintenance doses are 5, 10, and 15 mg

Zepbound is started at 2.5 mg once weekly purely as a run-in to let the gut adjust; that starting dose is not a maintenance dose and isn't expected to drive much weight loss2. From there the dose is raised in 2.5 mg steps, no closer than four weeks apart, with the three maintenance doses being 5, 10, and 15 mg once weekly2. So the real question — "which dose works best" — is a question about those three steps.

What SURMOUNT-1 showed: weight loss rises with dose

SURMOUNT-1 was the 72-week, placebo-controlled phase 3 trial in adults with obesity (or overweight plus a weight-related condition) without diabetes. It tested all three maintenance doses head-to-head against placebo, and the dose-response was clear1:

| Weekly maintenance dose | Mean weight change at 72 weeks | |-------------------------|--------------------------------| | 5 mg | about −15% | | 10 mg | about −19.5% | | 15 mg | about −20.9% | | Placebo | about −3.1% |

Read across that column and two things stand out. First, more dose did mean more weight loss — 15 mg beat 5 mg by roughly five to six percentage points of body weight on average1. Second, the gap between 10 mg and 15 mg is small — on the order of a percentage point or so. The steepest gain is moving from 5 mg to 10 mg; the jump from 10 mg to 15 mg adds comparatively little to the average. That flattening at the top of the curve is the single most useful fact for thinking about "most effective."

A systematic review pooling the tirzepatide weight-loss trials reached the same shape of conclusion: efficacy increases across the dose range, and so do gastrointestinal side effects, which are dose-dependent and concentrated during dose increases3. In other words, the cost of climbing to the top of the ladder is not zero.

§ Table 1 — SURMOUNT-1 Dose-Response (Obesity, No Diabetes, 72 Weeks)

Weekly doseMean weight loss at 72 wks≥20% loss (responders)Approx. GI AE signal
5 mg−15.0%30%Lower end of range
10 mg−19.5%50%Mid range
15 mg−20.9%57%Upper end of range
Placebo−3.1%3%Baseline
10 mg → 15 mg gap~1.4 percentage points~7 percentage pointsGI events continue to rise
Source: Jastreboff et al., NEJM 2022 (PMID 35658024). Approximate least-squares means from Phase 3 RCT, n=2539, 72 weeks. GI adverse event rates also rise with dose — the tolerability-vs-efficacy trade-off is steepest at the 10-to-15 mg step.

"Most effective" averages hide a lot of individual variation

Those trial figures are averages. Within every dose arm, some people lost far more than the mean and some far less — we unpack that spread, the responder rates, and how fast the loss accrues in Zepbound results: how much weight can you lose. A network meta-analysis comparing tirzepatide and semaglutide across doses confirmed tirzepatide's higher doses sit at the top for weight loss, but it is still reporting group-level estimates, not a guarantee for any one person4. Plenty of people reach their goal on 5 or 10 mg and never need 15 mg; others tolerate 15 mg well and want the extra effect. The "most effective dose" in a population average is a starting point for a conversation with a prescriber, not a target everyone should chase.

The trade-off the average doesn't show: tolerability

Effectiveness only counts if you can actually stay on the dose. The dominant Zepbound side effects are gastrointestinal — nausea, diarrhea, constipation, vomiting — and a network meta-analysis of GI adverse events across GLP-1-class drugs found these effects rise with dose and are worst during titration5. That is the whole reason the label mandates slow, stepped increases rather than starting high2.

So the practical definition of your most effective dose is: the lowest dose that gets you to your weight goal while keeping side effects tolerable enough to stay on it long-term. For some that's 10 mg; for others it's 15 mg; for others 5 mg is plenty. A dose you quit because of nausea delivers 0% weight loss, regardless of what the trial average says. The standard clinical move when a step is poorly tolerated is to hold longer at the current dose, or step back down, rather than push through — the schedule sets a floor on speed, not a mandate to reach 15 mg2. For the full titration sequence laid out as a reference, see our tirzepatide dosage chart, and for how each side-effect wave behaves at each step, our tirzepatide dosing ladder and side effects guide and the full Zepbound side effects breakdown.

Does a higher dose still help if you started at the bottom?

Yes — the dose-response means people who plateau on a lower dose can often gain additional loss by advancing, which is exactly why the ladder goes up to 15 mg1. SURMOUNT-3 is instructive here: participants who had already lost weight through an intensive lifestyle program then went on tirzepatide and lost substantially more, showing the drug adds effect on top of a lower baseline6. And SURMOUNT-4 showed the flip side — people who stopped tirzepatide after reaching a high dose regained much of the weight, while those who continued kept it off, underlining that whatever dose works, the effect depends on staying on an effective dose, not reaching a number once7 — which is exactly why there's no separate lower setting once you hit goal; see Zepbound maintenance dose after goal weight.

Most effective for what? Indication matters

For obstructive sleep apnea — a separate FDA-approved Zepbound use — the trials and label center on the 10 and 15 mg maintenance doses, not the lower steps2. So "most effective dose" can differ by why the drug is being used. For chronic weight management the full 5/10/15 mg range is on the table; for OSA the evidence base sits at the upper doses.

The honest bottom line

In the trial data, 15 mg once weekly produced the most weight loss, with 10 mg close behind and 5 mg lower — effectiveness genuinely rises with dose1. But the curve flattens between 10 and 15 mg while side effects keep climbing, so the dose that's "most effective" on a chart isn't automatically the one that's most effective for you35. The dose worth aiming for is the lowest one that reaches your goal and that you can comfortably stay on, decided with a prescriber — because a tolerated 10 mg beats an abandoned 15 mg every time. To weigh how to get brand Zepbound versus other routes, start with our best tirzepatide overview, and for the wider evidence picture see the tirzepatide evidence guide. Dose also drives price — the self-pay vial tiers in our Zepbound cost and savings guide explain why 7.5 mg and up cost the same flat rate.

Frequently asked questions

What dose of Zepbound is most effective for weight loss?

In the SURMOUNT-1 trial, the 15 mg once-weekly maintenance dose produced the most weight loss (about 21% on average over 72 weeks), with 10 mg close behind (about 19.5%) and 5 mg lower (about 15%). Effectiveness rises with dose, but the gap between 10 mg and 15 mg is small while side effects keep increasing, so the most effective dose for an individual is the lowest one that reaches their goal and stays tolerable.

Is 15 mg of Zepbound always better than 10 mg?

On average 15 mg produced slightly more weight loss than 10 mg in trials, but the difference is roughly one percentage point of body weight, while gastrointestinal side effects continue to rise with dose. Many people reach their goal on 10 mg and never need 15 mg. Whether to advance is an individual decision made with a prescriber, balancing extra benefit against tolerability.

Why is Zepbound started at 2.5 mg if it's not the most effective dose?

The 2.5 mg dose is a four-week run-in to let the digestive system adjust before stepping up; it is not a maintenance dose and isn't expected to drive much weight loss. The dose is then raised in 2.5 mg steps no closer than four weeks apart, because side effects are dose-dependent and worst during increases, so a slow climb keeps them manageable.

Does a higher Zepbound dose mean I'll keep the weight off?

Reaching an effective dose matters less than staying on it. In SURMOUNT-4, people who stopped tirzepatide after reaching a high dose regained much of the lost weight, while those who continued kept it off. The benefit depends on remaining on an effective, tolerated dose over time, not on hitting a particular number once.

Is the most effective Zepbound dose the same for sleep apnea?

For obstructive sleep apnea — a separate FDA-approved use of Zepbound — the trials and label center on the 10 and 15 mg maintenance doses rather than the lower steps. So the dose emphasis can differ by indication: the full 5/10/15 mg range applies to weight management, while the OSA evidence sits at the upper doses.

References(7)

  1. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, and the SURMOUNT-1 Investigators (2022). Tirzepatide Once Weekly for the Treatment of Obesity.. New England Journal of Medicine. PMID: 35658024. https://pubmed.ncbi.nlm.nih.gov/35658024/
  2. Eli Lilly and Company (FDA prescribing information via DailyMed) (2025). ZEPBOUND (tirzepatide) injection, for subcutaneous use — Prescribing Information (Dosage and Administration; Dosage Forms and Strengths).. DailyMed (U.S. National Library of Medicine), SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  3. Lin F, Yu B, Ling B, Lv G, Shang H, Zhao X, Jie X, Chen J, Li Y (2023). Weight loss efficiency and safety of tirzepatide: A Systematic review.. PLoS One. PMID: 37141329. https://pubmed.ncbi.nlm.nih.gov/37141329/
  4. Kasagga A, et al. (2025). Comparative Efficacy and Tolerability of Tirzepatide Versus Semaglutide at Varying Doses for Weight Loss in Non-diabetic Adults With Obesity: A Network Meta-Analysis of Randomized Controlled Trials.. Cureus. PMID: 40978842. https://pubmed.ncbi.nlm.nih.gov/40978842/
  5. Ismaiel A, et al. (2025). Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis.. International Journal of Obesity (London). PMID: 40804463. https://pubmed.ncbi.nlm.nih.gov/40804463/
  6. Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, Srivastava G, Halpern B, Zhang S, Chen J, Bunck MC, Ahmad NN, Forrester T, and the SURMOUNT-3 Investigators (2023). Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.. Nature Medicine. PMID: 37840095. https://pubmed.ncbi.nlm.nih.gov/37840095/
  7. Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, Ahmad NN, Zhang S, Liao R, Bunck MC, Jouravskaya I, Murphy MA, and the SURMOUNT-4 Investigators (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.. JAMA. PMID: 38078870. https://pubmed.ncbi.nlm.nih.gov/38078870/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Related monograph sections